ATRS Share Price

Open 1.69 Change Price %
High 1.74 1 Day 0.01 0.59
Low 1.69 1 Week 0.03 1.79
Close 1.71 1 Month 0.05 3.01
Volume 239826 1 Year 0.38 28.57
52 Week High 1.85
52 Week Low 0.67
ATRS Important Levels
Resistance 2 1.76
Resistance 1 1.74
Pivot 1.71
Support 1 1.68
Support 2 1.66
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
MSFT 59.66 4.21%
MSFT 59.66 4.21%
MSFT 59.66 4.21%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
NASDAQ USA Top Gainers Stocks
HMNY 9.90 76.47%
LOCM 0.09 50.00%
SCHS 0.12 33.33%
KONE 6.59 29.22%
WRES 0.09 28.57%
ALKS 55.62 27.83%
QKLS 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
PGRX 0.04 -42.86%

Antares Pharma, Inc. (NASDAQ: ATRS)

ATRS Technical Analysis 5
As on 21st Oct 2016 ATRS Share Price closed @ 1.71 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.13 & Strong Buy for SHORT-TERM with Stoploss of 1.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
ATRS Target for October
1st Target up-side 2.05
2nd Target up-side 2.31
3rd Target up-side 2.57
1st Target down-side 1.31
2nd Target down-side 1.05
3rd Target down-side 0.79
ATRS Other Details
Segment EQ
Market Capital 465712352.00
Sector Healthcare
Industry Medical Instruments & Supplies
Offical website
ATRS Address
100 Princeton South
Suite 300
Ewing, NJ 08628
United States
Phone: 609-359-3020
ATRS Latest News
Interactive Technical Analysis Chart Antares Pharma, Inc. ( ATRS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Antares Pharma, Inc.
ATRS Business Profile
Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol, for the treatment of overactive bladder. Antares also has a licensing agreement with Watson Watson Pharmaceuticals, Inc. (Watson) under which Watson will commercialize its topical oxybutynin gel 3% product in the United States and Canada. Its gel portfolio also includes Elestrin (estradiol gel) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies. The Company’s Pressure Assisted Injection Devices consists of three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. The injector employs a disposable plastic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle.